Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05562947
Other study ID # YR42983
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date June 28, 2024
Est. completion date May 7, 2029

Study information

Verified date June 2024
Source Hoffmann-La Roche
Contact Reference Study ID Number: YR42983, https://forpatients.roche.co
Phone 888-662-6728 (U.S. and Canada)
Email global-roche-genentech-trials@gene.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will evaluate the efficacy, safety, and pharmacokinetics of ranibizumab 100 mg/mL delivered Q24W via the PDS implant compared with ranibizumab 0.5 mg delivered as a Q4W intravitreal injection in Chinese patients with nAMD.


Recruitment information / eligibility

Status Recruiting
Enrollment 68
Est. completion date May 7, 2029
Est. primary completion date February 25, 2027
Accepts healthy volunteers No
Gender All
Age group 50 Years to 80 Years
Eligibility Inclusion Criteria: - Initial diagnosis of nAMD within 9 months prior to the screening visit - Previous treatment with at least three anti-VEGF intravitreal injections for nAMD per standard of care within 6 months prior to the screening visit - Demonstrated response to prior anti-VEGF intravitreal treatment since diagnosis - Availability of historical VA data prior to the first anti-VEGF treatment for nAMD up to the screening visit - BCVA of 34 letters or better (20/200 or better approximate Snellen equivalent), using Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters - All subtypes of nAMD lesions are permissible - Sufficiently clear ocular media and adequate pupillary dilation to allow for analysis and grading by the central reading center of FP, FA, ICGA, FAF, and OCT images Exclusion Criteria: Study Eye - History of vitrectomy surgery, submacular surgery, or other surgical intervention, all for AMD - Prior treatment with Visudyne, external-beam radiation therapy, or transpupillary thermotherapy - Previous treatment with corticosteroid intravitreal injection - Previous intraocular device implantation (not including intraocular lens implants) - Previous laser (any type) used for AMD treatment - Treatment with anti-VEGF agents other than ranibizumab within 1 month prior to the randomization visit - Concurrent conjunctival, Tenon's capsule, and/or scleral condition in the supero temporal quadrant of the eye that may affect the implantation, subsequent tissue coverage, and refill-exchange procedure of the PDS implant - Subretinal hemorrhage that involves the center of the fovea, if the hemorrhage is greater than 0.5 disc area (1.27 mm2) in size at screening - Subfoveal fibrosis or subfoveal atrophy - Retinal pigment epithelial tear - Any concurrent intraocular condition - Active intraocular inflammation (grade trace or above) - History of vitreous hemorrhage - History of rhegmatogenous retinal detachment - History of rhegmatogenous retinal tears or peripheral retinal breaks within 3 months prior to the randomization visit - History of pars plana vitrectomy surgery - Aphakia or absence of the posterior capsule - Spherical equivalent of the refractive error demonstrating more than 8 diopters of myopia - Preoperative refractive error that exceeds 8 diopters of myopia, for patients who have undergone prior refractive or cataract surgery - Intraocular surgery (including cataract surgery) within 3 months preceding the randomization visit - Uncontrolled ocular hypertension or glaucoma - History of glaucoma-filtering surgery, tube shunts, or microinvasive glaucoma surgery - History of corneal transplant Fellow (Non-Study) Eye • Non-functioning fellow eye Either Eye - Prior treatment with brolucizumab (at any time prior to the screening visit) - Prior participation in a clinical trial involving anti-VEGF drugs within 6 months prior to the randomization visit - Choroidal neovascularization due to other causes, such as ocular histoplasmosis, trauma, central serous chorio-retinopathy, or pathologic myopia - Any history of uveitis - Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis

Study Design


Related Conditions & MeSH terms


Intervention

Device:
PDS with ranibizumab (100 mg/mL)
Patients randomized to the implant arm will have the implant (filled prior to implantation with approximately 20 uL of the 100-mg/mL formulation of ranibizumab [approximately 2 mg dose of ranibizumab]) surgically inserted in the study eye at the Day 1 visit following their randomization visit, or at Week 48 visit for patients randomized to the intravitreal arm. After the initial fill of the implant with ranibizumab, patients will receive implant refill-exchanges at fixed 24-week intervals.
Drug:
Ranibizumab (10 mg/mL)
Patients in the intravitreal arm will receive their first intravitreal injection of 50 uL of the 10 mg/mL ranibizumab (0.5 mg dose) at the Day 1 visit, which will occur at the conclusion of the randomization visit. Afterward, patients will receive intravitreal ranibizumab injections of 50 uL of the 10 mg/mL formulation Q4W at each scheduled study visit until Week 44

Locations

Country Name City State
China Beijing Hospital Beijing City
China The Second Affiliated Hospital of Harbin Medical University; ophthalmology department Harbin
China Shanghai First People's Hospital Shanghai
China Tianjin Medical University Eye Hospital Tianjin City
China Eye Hospital, Wenzhou Medical University Wenzhou City

Sponsors (1)

Lead Sponsor Collaborator
Hoffmann-La Roche

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline in BCVA score averaged over Weeks 36 and 40, as assessed using the ETDRS visual acuity chart at a starting distance of 4 meters Baseline up to Week 40
Secondary Proportion of patients with BCVA score of 38 letters (20/200 approximate Snellen equivalent) or worse averaged over Weeks 36 and 40 Baseline up to Week 40
Secondary Proportion of patients with BCVA score of 38 letters (20/200 approximate Snellen equivalent) or worse averaged over Weeks 44 and 48 Baseline up to Week 48
Secondary Proportion of patients with BCVA score of 69 letters (20/40 approximate Snellen equivalent) or better averaged over Weeks 36 and 40 Baseline up to Week 40
Secondary Proportion of patients with BCVA score of 69 letters (20/40 approximate Snellen equivalent) or better averaged over Weeks 44 and 48 Baseline up to Week 48
Secondary Proportion of patients who gain =0 letters in BCVA score from baseline averaged over Weeks 36 and 40 Baseline up to Week 40
Secondary Proportion of patients who gain = 0 letters in BCVA score from baseline averaged over Weeks 44 and 48 Baseline up to Week 48
Secondary Proportion of patients who lose < 10 or > 5 letters in BCVA score from baseline averaged over Weeks 36 and 40 Baseline up to Week 40
Secondary Proportion of patients who lose < 10 or > 5 letters in BCVA score from baseline averaged over Weeks 44 and 48 Baseline up to Week 48
Secondary Change from baseline in CPT at Week 36 CPT = center point thickness Baseline up to Week 36
Secondary Change from baseline in CST at Week 36 CST = central subfield thickness Baseline up to Week 36
Secondary Change from baseline in CPT at Week 44 CPT = center point thickness Baseline up to Week 44
Secondary Change from baseline in CST at Week 44 CST = central subfield thickness Baseline up to Week 44
Secondary Proportion of patients in the implant arm who do not undergo supplemental treatment with intravitreal ranibizumab 0.5 mg before the first, second, third, fourth, fifth, and sixth fixed refill exchange intervals Baseline up to 144 weeks
Secondary Proportion of patients in the implant arm who do not undergo a supplemental treatment that requires subsequent additional supplemental treatments during the study Baseline up to 144 weeks
Secondary Proportion of participants with Adverse Events Baseline up to 144 weeks
Secondary Incidence and severity of adverse device effects in the PDS patients Baseline up to 144 weeks
Secondary Incidence, causality, severity, and duration of anticipated serious adverse device effects in the PDS patients Baseline up to 144 weeks
Secondary Observed serum ranibizumab concentrations at specified timepoints Baseline, Weeks 4, 12, 24, 28, 36, 48
Secondary Area under the concentration time curve from 0-24 weeks Baseline, Weeks 4, 12, 24
Secondary Maximum serum concentration of ranibizumab Baseline, Weeks 4, 12, 24, 28, 36, 48
Secondary Minimum serum concentration of ranibizumab Baseline, Weeks 4, 12, 24, 28, 36, 48
Secondary Prevalence of ADAs at baseline and incidence of ADAs during the study Baseline, Weeks 4, 24, 48
Secondary Incidence of treatment-emergent ADAs during the study Baseline, Weeks 4, 24, 48
See also
  Status Clinical Trial Phase
Completed NCT02251366 - NVAMD Satellite Study N/A
Unknown status NCT00767949 - Safety Study of iSONEP (Sonepcizumab/LT1009) to Treat Neovascular Age-related Macular Degeneration Phase 1
Completed NCT00764738 - Study Investigating OCT, Multifocal ERG, and Microperimetry in Monthly Versus PRN Ranibizumab in Neovascular Age-Related Macular Degeneration Phase 2/Phase 3
Completed NCT00383370 - Safety and Tolerability of Intravitreal VEGF Trap Formulations in Subjects With Neovacular AMD Phase 1
Completed NCT01678963 - Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD) Phase 2
Completed NCT03930641 - Study of the Safety of Brolucizumab 6 mg in Prefilled Syringe in Patients With Neovascular Age Related Macular Degeneration Phase 3
Completed NCT01863199 - Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Age-related Macular Degeneration (AMD) Phase 4
Completed NCT04239027 - A Study to Assess the Effects of Brolucizumab in Adult Patients With Neovascular Age Related Macular Degeneration Phase 3
Completed NCT00574093 - Efficacy and Safety Study of Lucentis (Ranibizumab) and Visudyne (Verteporfin) Combination Therapy in Neovascular AMD Phase 2
Completed NCT00685100 - Retinal Effects After Combined Photodynamic Therapy (PDT) With Intravitreal Triamcinolone Phase 3
Completed NCT01942213 - Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Intravitreal Injection of Ranibizumab vs. a Single Intravitreal Injection of Aflibercept in Treatment Naive and Treatment Experienced Patients. N/A
Recruiting NCT00640640 - The Effects of Bevacizumab and Ranibizumab on Ocular Pulse Amplitude in Neovascular Age Related Macular Degeneration (AMD) N/A